Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Extracorporeal shock wave therapy showed no clear difference in change in burn‐related pruritus NRS ( compared with sham (low certainty).
It is very uncertain whether doxepin cream changes adverse events (somnolence) compared with oral antihistamine (very low certainty).
The review found no eligible studies for this question.
Extracorporeal shock wave therapy may leads to higher pain Pressure pain threshold (PPT) ( compared with sham (low certainty).
Pulsed high‐intensity laser showed no clear difference in change in burn‐related pruritus Itch Severity Scale (ISS) ( compared with placebo laser (moderate certainty).
The review found no eligible studies for this question.
Pulsed high‐intensity laser showed no clear difference in pain VAS ( compared with placebo laser (moderate certainty).
The review found no eligible studies for this question.
Gabapentin showed no clear difference in change in burn‐related pruritus (VAS) ( compared with cetirizine (antihistamine) (low certainty).
Gabapentin may leads to lower adverse events (somnolence) compared with cetirizine (antihistamine) (low certainty).
The review found no eligible studies for this question.
Pregabalin showed no clear difference in change in burn‐related pruritus (VAS) ( compared with cetirizine with pheniramine maleate (antihistamine) (low certainty).
Pregabalin may leads to lower adverse events (drowsiness) compared with cetirizine with pheniramine maleate (antihistamine) (low certainty).
The review found no eligible studies for this question.
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).